Cancer patients are five times more likely to experience venous thromboembolism (VTE) than the general population.1 Second only to cancer itself, VTE is the second most common cause of mortality in cancer patients.2 According to previous clinical management recommendations, the typical VTE treatment in cancer patients involves the initial use of parenteral low-molecular-weight heparin (LMWH) followed by long-term use of oral vitamin K antagonists (VKA).3 However, recent recommendations proposed factor Xa inhibitors as one of the options of the main initial treatment for VTE.4 The gene discussed is F10; the disease is venous thromboembolism.